The present technology improves immunogenicity by treating DCs during maturation with the fungal-derived enzyme galactose oxidase. Hereby, a stronger physical interaction between DCs and T cells is achieved resulting in an at least 10-fold improved T cell priming capacity. In cell culture assays both human and mouse DCs showed enhanced T cell priming potential, the murine cells also in vivo. Even the T cell stimulatory potential of mature DCs that were putatively activated up to a maximum was further improved by the galactose oxidase treatment. Hence, low affine T lymphocytes, as often found in the context of tumor antigens, can be activated and brought to proliferation too. By improving T cell priming capability and therefore immunogenicity, this technology provides the opportunity to markedly enhance the classical DC maturation and accordingly to improve DC-vaccine approaches for example in tumor or HIV patients.
Further information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
email@example.com | TechnologieAllianz e.V.
New Lithium Salts of Pentafluorophenylamide Anions as Electrolytes in Lithium Ionic Batteries
18.04.2017 | TechnologieAllianz e.V.
Gratings on glass surfaces
28.03.2017 | TechnologieAllianz e.V.
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
18.08.2017 | Life Sciences
18.08.2017 | Physics and Astronomy
18.08.2017 | Materials Sciences